Medytox says, 'China's permit on Meditoxin is in progress'
Medytox says, 'China's permit on Meditoxin is in progress'
  • Kim Min-jee
  • 승인 2019.06.10 11:29
  • 댓글 0
이 기사를 공유합니다

Medytox dismissed rumors that the Chinese authority would suspend the screening of  the botulinum toxin "Meditoxin" that was expected to be licensed in China in the first half of the year.

Medytox said on its website on June 5 that it has not received any notification from China Food and Drug Administration (CFDA) that it will suspend the screening process of Meditoxin's license, and that those who will spread false information will be held fully responsible.

The rumor that Meditoxin was suspended from screening for Chinese license was raised by a news outlet. According to the report, the CFDA decided to suspend the license screening process after local science and technology media outlets dealt with negative suspicions regarding the manufacturing process of Medytox, which was recently raised in Korea.

Medytox, however, explained that the screening process for approval of Meditoxin, which is being carried out at CFDA, is in the process of reviewing final documents.

A Medytox official said, "The kind of noises that have been happening recently with the company are being caused by malicious tip-offs from former Medytox employees who have colluded with Daewoong Pharmaceutical, and will be over when Daewoong is found guilty of stealing strains and manufacturing process materials."

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.